

## Package leaflet: Information for the patient

**Ezetimibe/Atorvastatine Sandoz 10 mg/10 mg, filmomhulde tabletten**  
**Ezetimibe/Atorvastatine Sandoz 10 mg/20 mg, filmomhulde tabletten**  
**Ezetimibe/Atorvastatine Sandoz 10 mg/40 mg, filmomhulde tabletten**  
**Ezetimibe/Atorvastatine Sandoz 10 mg/80 mg, filmomhulde tabletten**

ezetimibe and atorvastatin

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What [Nationally completed name] is and what it is used for
2. What you need to know before you take [Nationally completed name]
3. How to take [Nationally completed name]
4. Possible side effects
5. How to store [Nationally completed name]
6. Contents of the pack and other information

### **1. What [Nationally completed name] is and what it is used for**

[Nationally completed name] is a medicine to lower increased levels of cholesterol. [Nationally completed name] contains ezetimibe and atorvastatin.

[Nationally completed name] is used in adults to lower levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, [Nationally completed name] raises levels of “good” cholesterol (HDL cholesterol).

[Nationally completed name] works to reduce your cholesterol in two ways. It reduces the cholesterol absorbed in your digestive tract, as well as the cholesterol your body makes by itself.

Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.

LDL cholesterol is often called “bad” cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing

can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.

HDL cholesterol is often called “good” cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another form of fat in your blood that may increase your risk for heart disease.

[Nationally completed name] is used for patients who cannot control their cholesterol levels by diet alone. You should stay on a cholesterol-lowering diet while taking this medicine.

[Nationally completed name] is used in addition to your cholesterol-lowering diet if you have:

- a raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial]) or elevated fat levels in your blood (mixed hyperlipidaemia)
  - that is not well controlled with a statin alone;
  - for which you have used a statin and ezetimibe as separate tablets.
- a hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You may also receive other treatments.
- heart disease. [Nationally completed name] reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalisation for chest pain

[Nationally completed name] does not help you lose weight.

## 2. What you need to know before you take [Nationally completed name]

### Do not take [Nationally completed name] if

- you are allergic to ezetimibe, atorvastatin or any of the other ingredients of this medicine (listed in section 6),
- you have or have ever had a disease that affects the liver,
- you have had any unexplained abnormal blood tests for liver function,
- you are a woman able to have children and are not using reliable contraception,
- you are pregnant, trying to become pregnant or are breast-feeding,
- you use the combination of glecaprevir/pibrentasvir in the treatment of hepatitis C.

### Warnings and precautions

Talk to your doctor or pharmacist before taking [Nationally completed name] if

- you have had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes,
- you have kidney problems,
- you have an under-active thyroid gland (hypothyroidism),
- you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems,

- you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other “statin” or “fibrate” medicines),
- you regularly drink a large amount of alcohol,
- you have a history of liver disease,
- you are older than 70 years,
- you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this product,
- you have or have had myasthenia (a disease with general muscle weakness including in some cases muscles used when breathing), or ocular myasthenia (a disease causing eye muscle weakness) as statins may sometimes aggravate the condition or lead to the occurrence of myasthenia (see section 4),
- you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and [Nationally completed name] can lead to serious muscle problems (rhabdomyolysis).

**Contact your doctor promptly if you experience unexplained muscle pain, tenderness, or weakness while taking [Nationally completed name].** This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin is known to cause muscle problems, and cases of muscle problems have also been reported with ezetimibe.

Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this.

Check with your doctor or pharmacist before taking [Nationally completed name]:

- if you have severe respiratory failure.

If any of these apply to you (or you are not sure), talk to your doctor or pharmacist before taking [Nationally completed name] because your doctor will need to carry out a blood test before and possibly during your [Nationally completed name] treatment to predict your risk of muscle-related side effects. The risk of muscle-related side effects, e.g. rhabdomyolysis, is known to increase when certain medicines are taken at the same time (see section 2 “Other medicines and [Nationally completed name]”).

While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.

Tell your doctor about all your medical conditions including allergies.

The combined use of [Nationally completed name] and fibrates (medicines for lowering cholesterol) should be avoided since the combined use of [Nationally completed name] and fibrates has not been studied.

### **Children**

[Nationally completed name] is not recommended for children and adolescents.

Other medicines and [Nationally completed name]

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without prescription.

There are some medicines that may change the effect of [Nationally completed name] or their effect may be changed by [Nationally completed name] (see section 3). This type of interaction could make one or both of the medicines less effective. Alternatively it could increase the risk or severity of side effects, including the important muscle wasting condition known as “rhabdomyolysis” described in section 4:

- ciclosporin (a medicine often used in organ transplant patients),
- erythromycin, clarithromycin, telithromycin, fusidic acid\*\*, rifampicin (medicines for bacterial infections),
- ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole (medicines for fungal infections),
- gemfibrozil, other fibrates, nicotinic acid, derivatives, colestipol, cholestyramine (medicines for regulating lipid levels),
- some calcium channel blockers used for angina or high blood pressure, e.g. amlodipine, diltiazem,
- digoxin, verapamil, amiodarone (medicines to regulate your heart rhythm),
- medicines used in the treatment of HIV, e.g. ritonavir, lopinavir, atazanavir, indinavir, darunavir, the combination of tipranavir/ritonavir, etc. (medicines for AIDS),
- some medicines used in the treatment of hepatitis C, e.g. telaprevir, boceprevir and the combination of elbasvir/grazoprevir,
- daptomycin (a medicine used to treat complicated skin and skin structure infections and bacteraemia).

**\*\*If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart [Nationally completed name]. Taking [Nationally completed name] with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.**

- Other medicines known to interact with [Nationally completed name]
  - oral contraceptives (medicines for preventing pregnancy),
  - stiripentol (an anticonvulsant medicine for epilepsy),
  - cimetidine (a medicine used for heartburn and peptic ulcers),
  - phenazone (a painkiller),
  - antacids (indigestion products containing aluminium or magnesium),
  - warfarin, phenprocoumon, acenocoumarol or fluindione (medicines to prevent blood clots),
  - colchicine (used to treat gout),
  - St John's wort (a medicine to treat depression).

**[Nationally completed name] with food and alcohol**

See section 3 for instructions on how to take [Nationally completed name]. Please note the following:

#### *Grapefruit juice*

Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of [Nationally completed name].

#### *Alcohol*

Avoid drinking too much alcohol while taking this medicine. See section 2 “Warnings and precautions” for details.

#### **Pregnancy and breast-feeding**

Do not take [Nationally completed name] if you are pregnant, are trying to get pregnant or think you may be pregnant. Do not take [Nationally completed name] if you are able to become pregnant unless you use reliable contraceptive measures. If you get pregnant while taking [Nationally completed name], stop taking it immediately and tell your doctor.

Do not take [Nationally completed name] if you are breast-feeding.

The safety of [Nationally completed name] during pregnancy and breast-feeding has not yet been proven.

Ask your doctor or pharmacist for advice before taking this medicine.

#### **Driving and using machines**

[Nationally completed name] is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking [Nationally completed name].

#### **[Nationally completed name] contains lactose**

[Nationally completed name] tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

#### **[Nationally completed name] contains sodium**

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

### **3. How to take [Nationally completed name]**

Always take this medicine exactly as your doctor has told you. Your doctor will determine the appropriate tablet strength for you, depending on your current treatment and your personal risk status. Check with your doctor or pharmacist if you are not sure.

- Before starting [Nationally completed name], you should be on a diet to lower your cholesterol.
- You should keep on this cholesterol-lowering diet while taking [Nationally completed name]

#### How much to take

The recommended dose is one [Nationally completed name] tablet by mouth once a day.

#### When to take

Take [Nationally completed name] at any time of the day. You can take it with or without food.

If your doctor has prescribed [Nationally completed name] along with cholestyramine or any other bile acid sequestrant (medicines for lowering cholesterol), you should take [Nationally completed name] at least 2 hours before or 4 hours after taking the bile acid sequestrant.

#### **If you take more [Nationally completed name] than you should**

Please contact your doctor or pharmacist.

#### **If you forget to take [Nationally completed name]**

Do not take an extra dose; just take your normal amount of [Nationally completed name] at the usual time the next day.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist

#### **4. Possible side effects**

Like all medicines, [Nationally completed name] can cause side effects, although not everybody gets them.

#### **If you experience any of the following serious side effects or symptoms, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.**

- serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing
- serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever; skin rash with pink-red blotches especially on palms of hands or soles of feet, which may blister
- muscle weakness, tenderness, pain or rupture or red-brown discolouration of urine and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems
- lupus-like disease syndrome (including rash, joint disorders and effects on blood cells)

You should consult your doctor as soon as possible if you experience problems with unexpected or unusual bleeding or bruising, because this may be suggestive of a liver complaint.

The following common side effects were reported (may affect up to 1 in 10 people):

- diarrhoea,
- muscle aches.

The following uncommon side effects were reported (may affect up to 1 in 100 people):

- the flu,
- depression; trouble sleeping; sleep disorder,
- dizziness; headache; tingling sensation,
- slow heartbeat,
- hot flush,
- shortness of breath,
- abdominal pain; abdominal bloating; constipation; indigestion; flatulence; frequent bowel movements; inflammation of the stomach; nausea; stomach discomfort; upset stomach,
- acne; hives,
- joint pain; back pain; leg cramps; muscle fatigue, spasms, or weakness; pain in arms and legs,
- unusual weakness; feeling tired or unwell; swelling, especially in the ankles (oedema),
- elevations in some laboratory blood tests of liver or muscle (CK) function,
- weight gain.

Additionally, the following side effects have been reported in people taking [Nationally completed name], or ezetimibe or atorvastatin tablets:

- allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment immediately),
- raised red rash, sometimes with target-shaped lesions,
- liver problems,
- cough,
- heartburn,
- decreased appetite; loss of appetite,
- high blood pressure,
- skin rash and itching; allergic reactions including rash and hives,
- tendon injury,
- gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting),
- inflammation of the pancreas often with severe abdominal pain,
- reduction in blood cell counts, which may cause bruising/bleeding (thrombocytopenia),
- inflammation of the nasal passages; nose bleed,
- neck pain; pain; chest pain; pain in the throat,
- increases and decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels),
- having nightmares,
- numbness or tingling in the fingers and toes,
- reduction of sensation to pain or touch,
- change in sense of taste; dry mouth,
- loss of memory,
- ringing in the ears and/or head; hearing loss,
- vomiting,
- belching,
- hair loss,
- raised temperature,

- urine tests that are positive for white blood cells,
- blurred vision; visual disturbances,
- gynaecomastia (breast enlargement in men).

Possible side effects reported with some statins

- sexual difficulties,
- depression,
- breathing problems including persistent cough and/or shortness of breath or fever,
- diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine,
- muscle pain, tenderness, or weakness that is constant and particularly if, at the same time, you feel unwell or have a high temperature that may not go away after stopping [Nationally completed name](frequency not known).
- Myasthenia gravis (a disease causing general muscle weakness including in some cases muscles used when breathing).

Ocular myasthenia (a disease causing eye muscle weakness).

Talk to your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision or drooping of your eyelids, difficulty swallowing, or shortness of breath.

### **Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the national reporting system listed in Appendix V.\* By reporting side effects you can help provide more information on the safety of this medicine.

## **5. How to store [Nationally completed name]**

Keep this medicine out of the sight and reach of children.

Do not take this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## **6. Contents of the pack and other information**

### **What [Nationally completed name] contains**

[Nationally completed name] 10 mg/ 10 mg: each film-coated tablet contains 10 mg of ezetimibe and 10 mg atorvastatin (as calcium trihydrate).

[Nationally completed name] 10 mg/ 20 mg: each film-coated tablet contains 10 mg of ezetimibe

and 20 mg atorvastatin (as calcium trihydrate).  
[Nationally completed name] 10 mg/ 40 mg: each film-coated tablet contains 10 mg of ezetimibe and 40 mg atorvastatin (as calcium trihydrate).  
[Nationally completed name] 10 mg/ 80 mg: each film-coated tablet contains 10 mg of ezetimibe and 80 mg atorvastatin (as calcium trihydrate).

The other ingredients are:

*Tablet core:*

cellulose microcrystalline 101 (E460), mannitol (E 421), calcium carbonate (E170), croscamellose sodium (E468), hydroxypropylcellulose (E463), polysorbate 80 (E433), iron oxide yellow (E172), magnesium stearate (E470b), povidone K29/32 (E1201), sodium laurilsulfate (E487).

*Tablet Coating*

[Nationally completed name] 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg - Opadry White OY-L-28900 consisting of:

Lactose monohydrate  
Hypromellose 2910 (E464)  
Titanium dioxide (E171)  
Macrogol 4000 (E1521)

[Nationally completed name] 10 mg/80 mg - DrCoat FCU consisting of:

Hypromellose 2910  
Titanium dioxide (E171)  
Talc (E553b)  
Macrogol 400  
Iron oxide yellow (E172)

**What [Nationally completed name] looks like and contents of the pack**

[Nationally completed name] 10 mg/ 10 mg film-coated tablets: White, round, biconvex film coated tablets, with diameter 8.1 mm approximately.

[Nationally completed name] 10 mg/ 20 mg film-coated tablets: White, ovaloid, biconvex film coated tablets, with dimensions 11.6 x 7.1 mm approximately.

[Nationally completed name] 10 mg/ 40 mg film-coated tablets: White, capsule shape, biconvex film coated tablets, with dimensions 16.1 x 6.1 mm approximately.

[Nationally completed name] 10 mg/ 80 mg film-coated tablets: Yellow, oblong, biconvex film coated tablets, with dimensions 19.1 x 7.6 mm approximately.

*[For NL/H/5668/001-004/DC:]*

*[Nationally completed name] 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg film-coated tablets*

OPA/Al/PVC//Al blisters containing 30, 90 and 100 film-coated tablets.

OPA/Al/PVC//Al perforated unit-dose blisters containing 30x1, 90x1 and 100x1 film-coated tablets.

*[Nationally completed name] 10 mg/80 mg film-coated tablets*

OPA/Al/PVC//Al blisters containing 30, multipack containing 90 (2 packs of 45) and multipack containing 100 (2 packs of 50) film-coated tablets.

OPA/Al/PVC//Al perforated unit-dose blisters of 30 x 1, multipack containing 90 x1 (2 packs

of 45 x 1) and multipack containing 100 x 1 (2 packs of 50 x 1) film-coated tablets.

*[For NL/H/5971/001-004/DC:]*

*[Nationally completed name] 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg film-coated tablets*  
OPA/Al/PVC//Al blisters containing 30 film-coated tablets.

Not all pack sizes may be marketed

#### **Houder van de vergunning voor het in de handel brengen en fabrikant**

##### Vergunninghouder

Sandoz B.V., Veluwezoom 22, 1327 AH Almere, Nederland

##### Fabrikanten

Elpen Pharmaceuticals Co. Inc.  
Marathonos Avenue 95  
19009, Pikermi, Attiki  
Griekenland

ELPEN Pharmaceutical Co. Inc.  
Zapani, Block 1048  
Keratea, 190 01  
Griekenland

Lek Pharmaceuticals d.d.  
Verovskova Ulica 57  
1526, Ljubljana  
Slovenië

#### **In het register ingeschreven onder:**

Ezetimibe/Atorvastatine Sandoz 10 mg/10 mg, filmomhulde tabletten	RVG 132479
Ezetimibe/Atorvastatine Sandoz 10 mg/20 mg, filmomhulde tabletten	RVG 132480
Ezetimibe/Atorvastatine Sandoz 10 mg/40 mg, filmomhulde tabletten	RVG 132481
Ezetimibe/Atorvastatine Sandoz 10 mg/80 mg, filmomhulde tabletten	RVG 132482

#### **Dit medicijn is geregistreerd in lidstaten van de Europese Economische Ruimte onder de volgende namen:**

Italië                      Scioplar

**Deze bijsluiter is voor het laatst goedgekeurd in oktober 2024**